Eisai and Biogen have a third regulatory approval for their amyloid-targeting Alzheimer’s disease therapy Leqembi, after it was greenlit by China’s National Medical Produc
Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than
Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.
Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.